- Home
- SLN vs LWAY Comparison
SLN vs LWAY Comparison
Compare SLN & LWAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLN
- LWAY
- Stock Information
- Founded
- SLN 1994
- LWAY 1986
- Country
- SLN United Kingdom
- LWAY United States
- Employees
- SLN N/A
- LWAY N/A
- Industry
- SLN Biotechnology: Pharmaceutical Preparations
- LWAY Packaged Foods
- Sector
- SLN Health Care
- LWAY Consumer Staples
- Exchange
- SLN Nasdaq
- LWAY Nasdaq
- Market Cap
- SLN 352.2M
- LWAY 355.7M
- IPO Year
- SLN N/A
- LWAY 1987
- Fundamental
- Price
- SLN $4.79
- LWAY $22.21
- Analyst Decision
- SLN Buy
- LWAY Hold
- Analyst Count
- SLN 4
- LWAY 1
- Target Price
- SLN $46.25
- LWAY N/A
- AVG Volume (30 Days)
- SLN 339.1K
- LWAY 37.9K
- Earning Date
- SLN 02-27-2025
- LWAY 03-19-2025
- Dividend Yield
- SLN N/A
- LWAY N/A
- EPS Growth
- SLN N/A
- LWAY 59.90
- EPS
- SLN N/A
- LWAY 0.86
- Revenue
- SLN $21,773,221.00
- LWAY $181,979,000.00
- Revenue This Year
- SLN N/A
- LWAY $19.38
- Revenue Next Year
- SLN $104.98
- LWAY $11.79
- P/E Ratio
- SLN N/A
- LWAY $25.85
- Revenue Growth
- SLN N/A
- LWAY 18.27
- 52 Week Low
- SLN $4.06
- LWAY $9.93
- 52 Week High
- SLN $27.72
- LWAY $28.61
- Technical
- Relative Strength Index (RSI)
- SLN 41.33
- LWAY 45.67
- Support Level
- SLN $4.71
- LWAY $21.89
- Resistance Level
- SLN $5.16
- LWAY $23.58
- Average True Range (ATR)
- SLN 0.47
- LWAY 0.82
- MACD
- SLN 0.08
- LWAY 0.05
- Stochastic Oscillator
- SLN 32.74
- LWAY 46.69
About SLN Silence Therapeutics Plc American Depository Share
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid. its pipeline products are; SLN360 therapy designed to temporarily block a specific gene's message that would otherwise trigger an unwanted effect. By silencing the LPA gene, the levels of Lp(a) are lowered, which in turn is expected to lower the risks of heart diseases, heart attacks, and strokes, and SLN124 therapy aims to temporarily silence TMPRSS6, a gene that prevents the liver from producing a particular hormone that controls iron levels in the body hepcidin. As hepcidin increases, iron levels in the blood are expected to decrease, which may increase the production of healthy red blood cells, thereby reducing anemia.
About LWAY Lifeway Foods Inc.
Lifeway Foods Inc is engaged in manufacturing probiotic, cultured, functional dairy health food products. Its primary product is drinkable kefir which is a cultured dairy product. Its product categories are Drinkable Kefir which is the key revenue-driving product, European-style soft cheeses, Cream, ProBugs, Frozen Kefir and Other dairy. The company manufacture and market products under the Lifeway and Fresh Made brand names, as well as under private labels on behalf of customers. It sells the products primarily through direct sales force, brokers, and distributors.